AdagrasibasibpembrolizumabsotorasibBI-2493G12CidocetaxeldaraxonrasibAZD4785RMC-7977
…d OS of 13.4 months,38 39 leading to full FDA approval in 2024. Adagrasib has also shown modest activity in PDAC (ORR 33%, PFS 5.4 months…
5articles mentioning drugs
7drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: ICB ×
ICB
This drug is selected. Its supporting articles are shown below.
Articles mentioning ICB
5 articles · page 1 of 191.9%
ICBMelanomanon-small-cell lung cancerStanford University
…7 and 38, which is reflective of this patient‘s non-response to ICB therapyAbstract 103 Figure 2Mapping of PD1/PD-L1 interactions T…
pembrolizumabpembrolizumab-treateddurvalumabLY2510924ICB-treatedAMD3100ICBBL-8040ICBplerixafor+1 more
…ssion quartiles in a subgroup of patients with CRC treated with pembrolizumab (n=500). The CXCR4high cohort showed significantly improved sur…
CCL20ICBICBrenal clear cell carcinomarenal cell carcinomaccRCCNature Biotechnologyadvanced clear cell renal cell carcinomaOncology Research Exchange Network
…tract 1229 Figure 1NF-κB signaling is associated with increased CCL20 (A) and increased anti-tumor lymphocytes (specifically effector…
NOX-A12ICBICBGlioblastomaGBMimmunotherapy
…xperienced CD8 T cells in i.c. and s.c. SB28 compared to ICB or NOX-A12 monotherapy. Additionally, the combination treatment increased …